Himalaya Therapeutics ('Himalaya'), a clinical-stage biopharmaceutical company, announced on Monday interim topline data update from the Mecbotamab vedotin (HTBA3011) in Non-Small Cell Lung Cancer (NSCLC) and certain sarcomas.

BioAtla (NASDAQ: BCAB), the company's collaboration partner, revealed operational updates on ongoing trials for HTBA3011 in patients with AXL-positive NSCLC who have earlier failed PD-1/L1, EGFR, or ALK inhibitor therapy. These trials covered patients from Greater China, where Himalaya has regional rights for the product candidate.

Interim phase two evaluation of the product in certain sarcomas supports advancement of patients with undifferentiated pleomorphic sarcoma and osteosarcoma into part two of the phase two trial. During phase one and part one of the phase two trial, partial responses (PRs) were seen in four of eight Undifferentiated Pleomorphic Sarcoma (UPS) patients - 50%. During phase one and part one of the phase two trial, PFS for osteosarcoma patients at three months was four of seven patients, or 57%.